Management and Health Laboratory, Institute of Management and EMbeDS Department, Scuola Superiore Sant'Anna, Pisa, Italy
Management and Health Laboratory, Institute of Management and EMbeDS Department, Scuola Superiore Sant'Anna, Pisa, Italy.
BMJ Open. 2020 Dec 3;10(12):e040738. doi: 10.1136/bmjopen-2020-040738.
The real-time continuous monitoring of vital parameters in patients affected by multiple chronic conditions and/or COVID-19 can lead to several benefits to the Italian National Healthcare System (IT-NHS). The UBiquitous Integrated CARE (UBICARE) technology is a novel health digital platform at the validation stage in hospital setting. UBICARE might support the urgent need for digitalisation and early intervention, as well as minimise the face-to-face delivery of care in both hospital and community-based care settings. This research protocol aims to design an early-stage assessment of the multidimensional impact induced by UBICARE within the IT-NHS alongside technology validation in a hospital ward.
The targeted patients will be medium/high-risk hypertensive individuals as an illustrative first example of how UBICARE might bring benefits to susceptible patients. A mixed-method study will be applied to incorporate to the validation study a multistakeholder perspective, including perceived patient experiences and preferences, and facilitate technology adoption. First, semistructured interviews will be undertaken with a variety of stakeholders including clinicians, health managers and policy-makers to capture views on the likely technology utility, economic sustainability, impact of adoption in hospital practice and alternative adoption scenarios. Second, a monocentric, non-randomised and non-comparative clinical study, supplemented by the administration of standardised usability questionnaires to patients and health professionals, will validate the use of UBICARE in hospital practice. Finally, the results of the previous stages will be discussed in a multidisciplinary-facilitated workshop with IT-NHS relevant stakeholders to reconcile stakeholders' perspectives. Limitations include a non-random recruitment strategy in the clinical study, small sample size of the key stakeholders and potential stakeholder recruitment bias introduced by the research technique.
The Ethics Committee for Clinical Experimentation of Tuscany Region approved the protocol. Participation in this study is voluntary. Study results will be disseminated through peer-reviewed publications and academic conferences.
实时连续监测受多种慢性疾病和/或 COVID-19 影响的患者的生命参数,可以为意大利国家医疗保健系统(IT-NHS)带来多项益处。UBiquitous Integrated CARE(UBICARE)技术是一种处于医院环境验证阶段的新型健康数字化平台。UBICARE 可能支持数字化和早期干预的迫切需求,同时最大限度地减少医院和社区护理环境中面对面的护理提供。本研究方案旨在设计在医院病房内进行技术验证的同时,评估 UBICARE 在 IT-NHS 中引起的多维影响的早期评估。
目标患者将是中/高危高血压患者,作为 UBICARE 如何使易感患者受益的第一个示例。将应用混合方法研究,将多利益相关者视角纳入验证研究,包括感知患者体验和偏好,并促进技术采用。首先,将对包括临床医生、卫生经理和政策制定者在内的各种利益相关者进行半结构化访谈,以了解他们对技术实用性、经济可持续性、在医院实践中的采用影响以及替代采用方案的看法。其次,将进行一项单中心、非随机和非对照的临床研究,并补充对患者和卫生专业人员进行标准化可用性问卷调查,以验证 UBICARE 在医院实践中的使用。最后,将在一个多学科促进的研讨会上讨论前几个阶段的结果,以协调 IT-NHS 相关利益相关者的观点。局限性包括临床研究中采用非随机招募策略、关键利益相关者的样本量小以及研究技术引入的潜在利益相关者招募偏差。
托斯卡纳地区临床试验伦理委员会批准了该方案。参与本研究是自愿的。研究结果将通过同行评审的出版物和学术会议进行传播。